INTRODUCTION
The hypothesis advanced by Recant and Riggs (1) , that free thyroxine concentration is a determinant of thyroxine turnover rate, is now supported by a considerable body of evidence (2) (3) (4) (5) . However, as Riggs points out, the observed second or-der relationship between serum thyroxine concentration and thyroxine turnover which seems to support the free thyroxine hypothesis would also result if thyroxine stimulated metabolic processes which are responsible for its own catabolism (6) . This would be consistent with the effect of thyroxine on the metabolism of other substances, e.g., insulin (7) , cortisol (8, 9) , and albumin ( 10, 11 ). Unfortunately, since the hormonal activity of thyroxine is generally proportional to free thyroxine concentration, a mass law effect of free thyroxine concentration on turnover is difficult to distinguish from an effect of hormonal action. To differentiate these effects it seemed advantageous to vary independently the concentration of free thyroxine and the metabolic activity of the hormone. With this purposewe undertook to investigate the relationship between free thyroxine concentration and thyroxine turnover during triiodothyronine suppression of thyroxine secretion. We anticipated that thyroid suppressive doses of triiodothyronine (12) would decrease free thyroxine concentration by decreasing total serum thyroxine concentration without diminishing the concentration of unoccupied thyroxine-binding sites. Since the hormonal action of triiodothyronine is similar to that of thyroxine, the metabolic effects of thyroid hormone would be maintained or possibly increased despite a decreased free thyroxine concentration.
METHODS
Studies were performed on six medical residents. None of the subjects had a history of thyroid disease, thyroid enlargement, or other clinical evidence of abnormal thyroid function. L-3,5,3'-Triiodothyronine 1 was administered in a dose of 25 ,Ag t.i.d. Thyroxine turnover and binding studies were performed during a control period and again during the 3rd wk of triiodothyronine treatment. The initial studies were done on subjects M. O., K. E., and N. 0. Subsequently, studies on S. C., M. C., and L. Y. were carried out. Different batches of thyroxine-I 2 were used to determine thyroxine binding and turnover in the two groups.
Serum thyroxine binding. The ratio of free to proteinbound thyroxine in serum, the free thyroxine fraction, FTF, was determined by ultrafiltration of serum containing predialyzed thyroxine-'I (13 
Thyroxine binding to individual serum proteins was assessed by conventional paper electrophoresis of sera containing thyroxine-'I in Tris-maleate buffer at pH 8.6 (14) . After electrophoresis, 'I activity on the paper strips was determined by an integrating, gas flow chromatogram scanner. The paper was then stained to identify serum proteins. Activity associated with each binding protein was expressed as a percentage of the total activity on the strip.
The subjects of this study received five drops of Lugol's solution twice daily to minimize thyroidal uptake of 'I. Serum iodothyronines were therefore separated from iodide by a resin column before measurement of iodine content.3 The method used does not distinguish between thyroxine and triiodothyronine.
Thyroxine metabolism. Thyroxine turnover was studied by following the decrease of serum radioactivity after the intravenous injection of a tracer dose of thyroxine-'I (15) . Thyroxine-'I was diluted to 10 ,uc/ml in 5%o human serum albumin on arrival and injected within 24 hr. The dose for each study was approximately 40 /kc.
A linear regression equation for the logarithm of serum radioactivity was obtained by the method of least squares. We have used the notation of Rall, Robbins, and Lewallen, (5) with some modification, in the turnover studies. In order to avoid possible bias introduced by graphic analysis of the regression line, values for the half-time of disappearance, ti, fractional disappearance rate, k, and the thyroxine distribution space, VsT4, were obtained directly from the regression equation. (See Appendix.) Serum thyroxine clearance, CST4, was calculated as follows: (7) or from equation 3: CST4 CT4 -=FTE (8) Statistical analysis of data was performed according to methods described by Snedecor (16) .
RESULTS
Except for one subject, M. I., who complained of insomnia and irritability, there was no evidence of increased thyroid hormone effect during triiodothyronine administration. However, basal meta- bolic rate was not measured, and a change in meta-rum thyroxi bolic rate cannot be excluded. Triiodothyronine lin (TBG) 'decreased serum iodothyronine-iodine concentra-ministration. tion in three subjects in whom it was measured thyroxine pe (Table I) . cant differen The results of thyroxine-binding studies are ine bound to shown in Table II . There was no consistent change nine treatme in FTF during triiodothyronine treatment. Since level of seru serum protein-bound thyroxine concentration ered to repr could not be determined in the presence of ex-If we assum ogenous triiodothyronine, [T4] was not estimated. rum thyroxi However, on the basis of the depression of iodo-subjects, the thyronine-iodine concentration in this and previous to the calcul studies (17) , it can be assumed that thyroxine about 5%. ( concentration was decreased by triiodothyronine thyroxine al( administration. In the absence of a change in FTF bound to TE this assumption leads to the conclusion that [T4] the average was also decreased.
thyroxine p( Electrophoretic analysis of serum thyroxine iodothyronin binding was done in five of the six subjects. In the normal r each of these subjects the percentage of total seThe incre< thyroxine-binding globulin; alb, albumin;
ine bound to thyroxine-binding globuincreased during triiodothyronine adAfter enrichment with 130 ug of r 100 ml, there was no longer a significe in the percentage of serum thyrox-TBG before and during triiodothyront. Thyroxine binding to TBG at this im thyroxine concentration is considesent the TBG binding capacity (3) . ie that the initial concentration of seine was within normal limits in these contribution of endogenous thyroxine lated binding capacity would be only Calculated on the basis of exogenous one, i.e., per cent serum thyroxine-131I BG x 130 jug of thyroxine per 100 ml, TBG binding capacity was 20 ,ug of er 100 ml both before and during triie administration. This value is within range for this method. TBG during triiodothyronine suppression was associated with decreased binding of thyroxine-131I to thyroxine-binding prealbumin (TBPA). Control levels of binding to TBPA were less than those reported by Ingbar and Freinkel, who used the same method (3). This discrepancy was probably due to trailing of prealbumin activity into the albumin zone in the present study. TBG and albumin were well separated in all electrophoretic analyses (Fig. 1) . TBPA capacity was not measured.
During triiodothyronine administration the fractional disappearance rate of thyroxine, k, increased in each subject (Fig. 2) . Fig. 3 shows the reciprocal relationship between k and the thyroxine distribution space, VST4. Since thyroxine clearance, CST4, is the product of k and VST4, it reflects the opposing tendencies of changes in these factors. Consequently, the increase in CST4 was relatively smaller than the increase in k. The effects of k and VST4 on CST4 are illustrated by the relation of control and treatment points to isobars of constant CST4 in Fig. 3 . The clearance of free thyroxine, CT4, was increased in five of the six subjects. The relative magnitude of the average increase in CT4 was slightly but not significantly greater than that of the increase in CST4 (Table III) .
DISCUSSION
The FTF is determined by the concentration (and association constants) of unoccupied thyroxinebinding sites (18 days) sufficient to produce thyrotoxicosis medicamentosa and an accelerated fractional disappearance of thyroxine-1311 did not affect the electrophoretic distribution of thyroxine or the binding capacity of TBG (21) . Unfortunately these studies were done in Veronal buffer which, as Ingbar subsequently demonstrated, inhibits prealbumin binding of thyroxine (22) . If, as occurs in Graves' disease, prealbumin-binding capacity was decreased in these patients FTF would have been increased despite a normal TBG capacity. At the lower doses of triiodothyronine used in the present study and with electrophoresis in Tris-maleate buffer, the percentage of thyroxine bound to TBG increased. This increase did not appear to be due to an increase in the total concentration of TBG since, at a high concentration of added cold thyroxine, binding patterns were similar in control sera and during triiodothyronine treatment. It is possible that increased binding to TBG occurred as a result of decreased prealbumin binding capacity but this seems unlikely since FTF was not increased.
ogenous triiodothyronine to serum iodothyronine-iodine would be only 0.2 ,ug/100 ml. If this value is correct the decrease in iodothyronine concentration would be almost proportional to the decrease in iodothyronine-iodine concentration. The increased percentage of serum thyroxine bound to TBG during triiodothyronine seems most consistent with the known inverse relationship between the percentage of serum thyroxine bound to TBG and total serum thyroxine concentration (2) . In contrast to the insensitivity of the FTF to small changes in thyroxine concentration, Ingbar and Freinkel have shown that the addition to serum of as little as 2.0 pg of thyroxine per 100 ml (or 1.3 ug of thyroxine iodine) decreases the fraction of serum thyroxine bound to TBG (3) .
The average fractional disappearance rate (k = 11.47%) in these subjects during the control period is similar to that observed by Gregerman, Gaffney, and Shock (23) in the same age group. Previous studies of thyroxine turnover and binding have shown that k usually varies inversely with serum thyroxine-binding affinity. Thus where binding affinity is increased as in myxedema, estrogen treatment, and idiopathic hyperTBGemia, k is decreased. Conversely, where serum-binding affinity is decreased as in thyrotoxicosis, salicylate treatment, and hypoTBGemia, k increases (3, 5) .
In the present study k increased during triiodothyronine administration whereas the free thyroxine fraction and its reciprocal, serum thyroxine-binding affinity, remained unaltered. It is reasonable to conclude that the more rapid k during triiodothyronine treatment was not due to an increased proportion of free thyroxine in serum. However, it is possible that part of the increase in k resulted from the decreased VST,. This hypothesis would imply that contraction of VST4 increased the proportion of exchangeable thyroxine in the subcompartment of VST4 from which thyroxine is actively removed. An advantage of calculating clearance rather than fractional disappearance rate is that the former is unaffected by reciprocal changes in volume of distribution and fractional disappearance rate. If the decreased VST4 were sufficient explanation for the acceleration of k by triiodothvronine, k x VST4, or CST4 would be constant. The increase in CST4 shows that the acceleration of k is out of proportion to, and therefore not entirely explained by, the contraction of VST4. It also appears that increased clearance contribtntes to the depression of serum thyroxine concentration during triiodothyronine administration. during triiodothyronine administration is difficult to explain. It seems unlikely that it was due to increased competition for the exchangeable thyroxine by serum proteins, since the total binding affinity of these proteins (as measured by the FTF) was not significantly increased. The decrease in VST, may be related to redistribution of thyroxine among the serum thyroxine-binding proteins. However, this hypothesis is subject to the criticism that VST4 is not consistently affected in clinical conditions where the electrophoretic distributioni of thyroxine is markedly altered. Possibly triiodothyronine decreased the binding affinity of cellular sites, but this is entirely speculative.
The hypothesis that free thyroxine is available to cellular sites that remove thyroxine from the exchangeable thyroxine pool implies that, ceteris paributs, changes in the concentration of free thy5However, the calculated values of VST4 must be accepted with some reservations. Whereas most estimates of VST4 have been obtained by extrapolation of the regression line to injection time, this method is subject to the criticism that it assumes that the fractional rate at which thyroxine-"1'I is removed from the exchangeable thyroxine pool during equilibration is the same as k at equilibrium. Another source of error is the presence in the tracer of rapidly cleared radioactive contaminants which presumably lead to overestimation of VST4 (24) . Serum iodide-3'I derived from thyroxine-'31I leads to underestimation of VST4, but, because of the rapid clearance of iodide, this is no more than 1 or 2% and can be disregarded (25, 26) . roxine will result in similar changes in thyroxine turnover. Effects on thyroxine binding and turnover in a variety of situations have been at least qualitatively consistent with this hypothesis (5). However, a number of observations suggest that thyroxine turnover may change without proportional changes in binding. The persistence of an altered fractional thyroxine turnover rate after treatment of thyrotoxicosis (21) or hypothyroidism (27) , the age-related decrease in turnover rate (23, 28) , and the early postoperative changes in thyroxine turnover (29) Chodos that cellular metabolic rate has a major role in regulating thyroxine turnover (31) . 
ADDENDUM
Since this manuscript was submitted for publication, Nicoloff and Dowling (32) have demonstrated that the fractional deiodination rate of labeled thyroxine is slowest immediately after injection and gradually increases as the tracer equilibrates in the exchangeable thyroxine pool. Similar results were obtained independently in this laboratory. 6 The slower deiodination of tracer thyroxine during equilibration leads to an overestimation of the zero time intercept, (b), by the extrapolation method and a consequent understimation of VST4. Acceleration of k would exaggerate this effect and was probably at least partially responsible for the otherwise unexplained contraction of VST4 during triiodothyronine administration. The calculated increase in CST4 and CT4 during triiodothyronine administration should therefore be regarded as minimal estimates. The actual increase in these clearances was probably more nearly proportional to the increase in k.
